SCMP - Sucampo Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
10.35
0.00 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close10.35
Open10.35
Bid0.00 x 0
Ask0.00 x 0
Day's Range10.25 - 10.50
52 Week Range9.30 - 17.55
Volume386,406
Avg. Volume504,370
Market Cap480.34M
Beta0.74
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Alnylam's RNAi Candidate Gains Breakthrough Therapy Status
    Zacks18 hours ago

    Alnylam's RNAi Candidate Gains Breakthrough Therapy Status

    Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.

  • Top 10 Stocks Under $20
    Zacksyesterday

    Top 10 Stocks Under $20

    Today we've highlighted ten stocks that are currently trading for under $20 per share. All of these stocks currently have a Zacks Rank #1 (Strong Buy), and a variety of other factors make these companies stand out as having strong upside potential.

  • Roche Reports Positive Data From Tecentriq Combination Study
    Zacks2 days ago

    Roche Reports Positive Data From Tecentriq Combination Study

    Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.

  • Galapagos' CF Candidate Shows Potential in Phase II Study
    Zacks2 days ago

    Galapagos' CF Candidate Shows Potential in Phase II Study

    Galapagos' (GLPG) CFTR corrector candidate, GLPG2222, shows potential in a phase II study on CF patients.

  • Incyte (INCY) Initiates Essential Thrombocythemia Trial
    Zacks6 days ago

    Incyte (INCY) Initiates Essential Thrombocythemia Trial

    Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.

  • Achillion (ACHN) Shares Down as J&J Announces Stake Sale
    Zacks7 days ago

    Achillion (ACHN) Shares Down as J&J Announces Stake Sale

    Achillion's (ACHN) shares fell following the announcement that J&J will sell its complete stake in the company.

  • Valeant (VRX) Announces Pricing of Senior Secured Notes
    Zacks7 days ago

    Valeant (VRX) Announces Pricing of Senior Secured Notes

    Valeant (VRX) prices its senior secured notes. The proceeds of the notes will be used to pay down its existing debt.

  • Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test
    Zacks7 days ago

    Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

    Roche's (RHHBY) diagnostic portfolio gets a further boost with FDA's clearance for Ventana tests.

  • Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee
    Zacks7 days ago

    Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee

    Pacira (PCRX) announced that the FDA has asked for an Advisory Committee Meeting to review the supplemental New Drug Application for expanded indication of Exparel in the nerve block setting.

  • Cardinal Health (CAH) to Divest Assets to Shanghai Pharma
    Zacks7 days ago

    Cardinal Health (CAH) to Divest Assets to Shanghai Pharma

    Cardinal Health (CAH) will streamline its Chinese operations by disposing pharmaceutical and medical products distribution business in China.

  • Capital Cube9 days ago

    ETFs with exposure to Sucampo Pharmaceuticals, Inc. : November 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sucampo Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to SCMP-US. Comparing the performance and risk of Sucampo Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
    Capital Cube19 days ago

    Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017

    Categories: Yahoo FinanceGet free summary analysis Sucampo Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Sucampo Pharmaceuticals, Inc. – Progenics Pharmaceuticals, Inc., Pfizer Inc., Abbott Laboratories and Ironwood Pharmaceuticals, Inc. Class A (PGNX-US, PFE-US, ABT-US and IRWD-US) that have also reported for this ... Read more (Read more...)

  • Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View
    Zacks20 days ago

    Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View

    Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in the United States and Japan, which drove the company's top line in Q3. The company is also working on expanding its Amitizia's label.

  • Thomson Reuters StreetEvents20 days ago

    Edited Transcript of SCMP earnings conference call or presentation 1-Nov-17 12:30pm GMT

    Q3 2017 Sucampo Pharmaceuticals Inc Earnings Call

  • Capital Cube21 days ago

    ETFs with exposure to Sucampo Pharmaceuticals, Inc. : November 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sucampo Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to SCMP-US. Comparing the performance and risk of Sucampo Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Associated Press21 days ago

    Sucampo tops 3Q revenue forecasts

    On a per-share basis, the Rockville, Maryland-based company said it had profit of 19 cents. Earnings, adjusted for one-time gains and costs, came to 27 cents per share. The biopharmaceutical company posted ...

  • Capital Cubelast month

    ETFs with exposure to Sucampo Pharmaceuticals, Inc. : October 17, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sucampo Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to SCMP-US. Comparing the performance and risk of Sucampo Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : October 4, 2017
    Capital Cube2 months ago

    Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : October 4, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sucampo Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Sucampo Pharmaceuticals Inc (SCMP): What Does It Mean For Your Portfolio?
    Simply Wall St.2 months ago

    Sucampo Pharmaceuticals Inc (SCMP): What Does It Mean For Your Portfolio?

    If you are looking to invest in Sucampo Pharmaceuticals Inc’s (NASDAQ:SCMP), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • Capital Cube2 months ago

    ETFs with exposure to Sucampo Pharmaceuticals, Inc. : September 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sucampo Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to SCMP-US. Comparing the performance and risk of Sucampo Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
    Capital Cube2 months ago

    Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017

    Categories: Yahoo FinanceGet free summary analysis Sucampo Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Sucampo Pharmaceuticals, Inc. – Nektar Therapeutics, Progenics Pharmaceuticals, Inc., Pfizer Inc., Akorn, Inc., Ironwood Pharmaceuticals, Inc. Class A, Synergy Pharmaceuticals, Inc., Abbott Laboratories and Evoke Pharma, Inc. (NKTR-US, ... Read more (Read more...)

  • Sucampo (SCMP) Up 17.1% Since Earnings Report: Can It Continue?
    Zacks2 months ago

    Sucampo (SCMP) Up 17.1% Since Earnings Report: Can It Continue?

    Sucampo (SCMP) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : August 22, 2017
    Capital Cube3 months ago

    Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : August 22, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sucampo Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Sucampo Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCMP) : August 17, 2017
    Capital Cube3 months ago

    Sucampo Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCMP) : August 17, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Sucampo Pharmaceuticals, Inc. a score of 53. Our analysis is based on comparing Sucampo Pharmaceuticals, Inc. with the following peers – Progenics Pharmaceuticals, Inc., Nektar Therapeutics, Pfizer Inc., Akorn, Inc., Evoke Pharma, Inc., Abbott Laboratories, RegeneRx Biopharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc. Class A and Synergy Pharmaceuticals, Inc. ... Read more (Read more...)